Press ReleaseView printer-friendly version << Back
Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy
Conference call and webcast
Webcast may be accessed via the Investor and Media page of the Audentes website
Call may be accessed by dialing (833) 659-8620 (U.S.) or (409) 767-9247 (international) and using conference ID# 8879216
"Today's announcement represents a significant step forward in expanding our scientific platform and deepening our pipeline of product candidates for neuromuscular diseases with high unmet medical need," stated
"We are excited to be collaborating with Audentes to advance these novel, highly differentiated approaches for DMD and DM1," stated Dr. Flanigan,Director of
Vectorized exon skipping uses an AAV vector to deliver an antisense sequence designed to induce cells to skip over faulty or misaligned sections of genetic code, leading to the expression of a more complete, functional protein. For the treatment of DMD, this approach has the potential to provide significant advantages over microdystrophin gene replacement strategies that produce a substantially truncated protein, which may limit the degree and durability of disease correction, as well as existing ASO therapies, whose efficacy is limited by poor biodistribution to muscle tissue.
Audentes and Nationwide Children's are collaborating to develop AT702, an AAV-antisense candidate designed to induce exon 2 skipping for DMD with duplications of exon 2 and mutations in exons 1-5 of the dystrophin gene. In preclinical studies of mice with exon 2 duplications, AT702 demonstrated robust proof-of-concept with dose-dependent increases in production of wild type or near-wild type length dystrophin protein and improvements in muscle function. Audentes is currently conducting additional preclinical work and expects to commence a Phase 1/2 study at Nationwide Children's in the fourth quarter of 2019.
Separate from the Nationwide Children's collaboration, Audentes is also conducting preclinical work to advance AT751 and AT753, additional vectorized exon skipping candidates, to treat DMD patients with genotypes amenable to exon 51 and exon 53 skipping. Both AT751 and AT753 utilize the same vector construct backbone as AT702, enabling a potentially accelerated path into clinical development. With these initial programs, Audentes is targeting more than 25% of patients with DMD, and has plans to leverage its vectorized exon skipping platform to develop further product candidates to address up to 80% of DMD patients over time.
In addition, Audentes and Nationwide Children's are evaluating vectorized RNA knockdown and vectorized exon skipping for myotonic dystrophy type 1 (DM1). Both approaches are designed to prevent the accumulation of toxic dystrophia myotonica-protein kinase (DMPK) RNA in affected cells, thereby restoring normal cellular function. RNA knockdown and exon skipping have both been clinically validated in studies with ASOs. As with DMD, combining these approaches with AAV delivery is expected to overcome the biodistribution limitations of ASO-based therapies. Preclinical studies are underway, and Audentes expects an IND for the selected product candidate, AT466, to be filed in 2020.
Audentes plans to leverage its proprietary AAV gene therapy technology platform, consisting of end-to-end internal expertise from vector construct engineering to state-of the-art large-scale cGMP manufacturing, to rapidly advance these programs from discovery through clinical development. Internal process and analytical development, fill-finish, and QC testing capabilities complete the company's fully-integrated approach to production and release of product candidates for clinical and commercial use. The current 1,000-liter scale manufacturing operation provides enough capacity for global commercialization of the company's lead program AT132, as well as continued clinical development of pipeline programs, and the facility is designed for expansion to include an additional 8,000 liters of production capacity.
About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is the most common type of muscular dystrophy in children, affecting approximately 1 in 3,500 to 5,000 male births, with more than 300,000 patients living with the disease worldwide. DMD is caused by mutations in the dystrophin gene, which encodes the protein dystrophin, a structural protein involved in maintaining muscle cell integrity. Patients with DMD typically develop muscle weakness in the early years of life and become wheelchair-bound in their early teens. As the disease progresses, patients typically develop respiratory, orthopedic, and cardiac complications. Cardiomyopathy and breathing difficulties usually begin by the age of 20, and few individuals with DMD live beyond their thirties. There is no cure for DMD, and for most patients, there are no satisfactory symptomatic or disease-modifying treatments.
About Myotonic Dystrophy Type 1
Myotonic dystrophy type 1 (DM1), is a rare, neuromuscular disease that affects multiple organ systems, and is characterized primarily by myotonia and progressive muscle wasting and weakness. DM1 has several forms which range in age of presentation and severity, including congenital, infantile, juvenile, and adult (classic). There are more than 100,000 patients living with DM1 across
For more information regarding Audentes, please visit www.audentestx.com.
Named to the Top 10 Honor Roll on
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the timing and nature of research and development activities, the nature of the results of data, the timing of regulatory filings, the expected market size of DMD and DM1 and potential penetration into those markets, anticipated manufacturing activities and the expected benefits of the company's product candidates and technology platform. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, the company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company's ability to advance its product candidates, obtain regulatory approval of and ultimately commercial its product candidates, the timing and results of preclinical and clinical trials, the company's ability to fund development activities and achieve development goals, the company's ability to protect intellectual property and other risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the
View original content to download multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-announces-expansion-of-aav-technology-platform-and-pipeline-with-new-development-programs-for-duchenne-muscular-dystrophy-and-myotonic-dystrophy-300825843.html